Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models

J Invest Dermatol. 2018 Jun;138(6):1260-1267. doi: 10.1016/j.jid.2018.01.005. Epub 2018 Jan 31.


Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies to COL17. Currently, systemic corticosteroids are used as first-line treatments for BP; alternatively, intravenous administration of high-dose IgG (IVIG) has been shown to be effective for patients with steroid-resistant BP in clinical practice. However, the effect of IVIG on BP has not fully been investigated. To examine the effects and mechanisms of action of IVIG against BP, we performed IVIG experiments using two experimental BP mouse models. One is a passive-transfer BP model that reproduces subepidermal separation in neonatal mice by the passive transfer of IgGs against COL17, such as polyclonal or monoclonal mouse IgG or IgG from BP patients. The other is an active BP model that continuously develops a disease phenotype in adult mice. IVIG decreased pathogenic IgG and the disease scores in both models. Injected IVIG distributed throughout the dermis and the intercellular space of the lower epidermis. Notably, IVIG inhibited the increase of IL-6 in both models, possibly by suppressing the production of IL-6 by keratinocytes. These results suggest that the inhibitory effects of IVIG on BP are associated with the reduction of pathogenic IgG and the modulation of cytokine production.

MeSH terms

  • Administration, Intravenous
  • Animals
  • Autoantibodies / blood*
  • Autoantibodies / immunology
  • Autoantigens / genetics
  • Autoantigens / immunology
  • Cell Line
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Humans
  • Immunization, Passive / methods
  • Immunoglobulin G / administration & dosage*
  • Immunoglobulins, Intravenous / administration & dosage*
  • Interleukin-6 / blood*
  • Interleukin-6 / immunology
  • Interleukin-6 / metabolism
  • Keratinocytes / drug effects
  • Keratinocytes / metabolism
  • Keratinocytes / microbiology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Non-Fibrillar Collagens / genetics
  • Non-Fibrillar Collagens / immunology
  • Pemphigoid, Bullous / blood
  • Pemphigoid, Bullous / drug therapy*
  • Pemphigoid, Bullous / immunology
  • Severity of Illness Index
  • Skin / immunology
  • Skin Transplantation / methods
  • Treatment Outcome


  • Autoantibodies
  • Autoantigens
  • Immunoglobulin G
  • Immunoglobulins, Intravenous
  • Interleukin-6
  • Non-Fibrillar Collagens
  • collagen type XVII
  • interleukin-6, mouse